Clinical Key Takeaways
lightbulb
- The PivotThis study suggests we can proactively risk-stratify Crohn's patients based on colonoscopic findings, potentially preventing loss of response. This goes beyond the traditional 'wait and see' approach after starting a new therapy.
- The DataSpecific parameters, like the presence of ulcers or a high Simple Endoscopic Score for Crohn’s Disease (SES-CD), were associated with an increased risk of primary non-response or loss of response to anti-TNF therapy.
- The ActionWhen performing a colonoscopy on a Crohn's patient initiating or already on anti-TNF therapy, meticulously document endoluminal features like ulcer characteristics and SES-CD. Use this information to guide more frequent monitoring and potentially earlier treatment intensification.
Guideline Context
Current guidelines from organizations like the American Gastroenterological Association (AGA) and the European Crohn's and Colitis Organisation (ECCO) emphasize a treat-to-target approach in Crohn's disease, aiming for both clinical and endoscopic remission. These guidelines recommend regular monitoring of disease activity using clinical indices and endoscopic evaluation, particularly when considering treatment escalation or de-escalation. However, they do not provide specific, validated endoluminal parameters for *proactively* predicting loss of response to therapy. This study offers a potential refinement to those guidelines, suggesting that certain endoscopic features at baseline or early in treatment could identify patients who need closer monitoring or a more aggressive initial approach. It's worth noting that the NICE guidelines also highlight the importance of shared decision-making with patients, and the information from this study could inform those discussions, allowing patients to better understand their individual risk and treatment options.
Identifying At-Risk Patients
So, what parameters should we be paying attention to? The study highlights several factors. The presence of deep ulcers, a high SES-CD score, and specific ulcer characteristics were all associated with a higher likelihood of primary non-response or loss of response to anti-TNF agents. Specifically, patients with a SES-CD score above a certain threshold (the exact value will need further validation) should be considered at higher risk. We also need to pay attention to the morphology of the ulcers themselves - are they deep and penetrating, or more superficial? Are they located in specific regions of the colon? The more high-risk features present, the more concerned we should be.
Adjusting Treatment Plans
How can we use this information to adjust our treatment plans? For patients identified as high-risk based on these endoluminal parameters, several strategies could be considered. One option is to intensify therapy from the outset, using combination therapy (e.g., anti-TNF plus immunomodulator) rather than monotherapy. Another approach is to implement more frequent monitoring, with earlier repeat endoscopies to assess response to therapy. If early signs of treatment failure are detected, we can then escalate therapy more quickly, before irreversible damage occurs. It's also important to optimize non-pharmacological interventions, such as dietary modifications and smoking cessation, which can impact treatment response.
Study Limitations
Before we overhaul our clinical practice, it's essential to acknowledge the limitations of this study. The sample size, while multi-center, may still be relatively small, limiting the generalizability of the findings. The study design is retrospective, which introduces the potential for bias. Furthermore, the definition of 'loss of response' can vary across studies and clinical settings, making it difficult to compare results. Finally, the study focuses primarily on anti-TNF therapy, and it's unclear whether these endoluminal parameters are predictive of response to other classes of medications used in IBD, such as vedolizumab or ustekinumab. A prospective, randomized controlled trial is needed to confirm these findings and determine the optimal management strategy for patients identified as high-risk.
Financial Considerations
Implementing more frequent monitoring and potentially escalating therapy earlier will undoubtedly have financial implications. More frequent endoscopies increase costs for both patients and the healthcare system. Combination therapy is generally more expensive than monotherapy. We need to consider the cost-effectiveness of these strategies. Will the potential benefits of preventing loss of response and avoiding complications outweigh the increased upfront costs? Furthermore, insurance coverage for more frequent endoscopies may be a barrier for some patients. Addressing these financial considerations is crucial to ensure equitable access to optimal care.
This study highlights the potential for a more proactive, personalized approach to managing Crohn's disease. By incorporating endoluminal parameters into our assessment of patients, we can potentially identify those at higher risk of treatment failure and tailor our management strategies accordingly. This could lead to improved outcomes, reduced complications, and a better quality of life for our patients. The increased costs of early intervention need to be balanced against the long term costs of managing complications from uncontrolled disease. Clear documentation of endoscopic findings and the rationale for treatment decisions will be essential for justifying these approaches to payers. We also need to educate patients about the rationale for more frequent monitoring and the potential benefits of early treatment intensification, ensuring that they are active participants in the decision-making process.
LSF-9786410402
How to cite this article
Lopes W. Endoluminal markers predict crohn's treatment failure. The Life Science Feed. Published January 1, 2026. Accessed April 19, 2026. https://thelifesciencefeed.com/gastroenterology/inflammatory-bowel-diseases/endoluminal-markers-predict-crohn-s-treatment-failure.
Copyright and license
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Fact-Checking & AI Transparency
This article was researched and drafted with AI assistance, then reviewed and approved for publication by the Editor. All content is sourced from peer-reviewed, open-access research. It does not represent the views of any pharmaceutical company or healthcare provider.
Our AI tools are used to summarise and structure published research only. Every article is checked by a human editor before going live — no article is published without editorial review.
References
- Ungaro, R., et al. (2017). American Gastroenterological Association guidelines on the management of Crohn's disease. Gastroenterology, 153(3), 825-848.
- Magro, F., et al. (2023). Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, diagnosis, established and emerging indications for therapy. Journal of Crohn's and Colitis, 17(1), 22-47.
- Turner, D., et al. (2021). Management of Crohn’s disease in adults. BMJ, 375, n2837.
- Raine, T., et al. (2020). ECCO guidelines on therapeutics in Crohn's disease: medical treatment. Journal of Crohn's and Colitis, 14(1), 2-22.